CANbridge Pharmaceuticals Inc. (HK:1228)
:1228
Want to see HK:1228 full AI Analyst Report?
Total Valuation
CANbridge Pharmaceuticals Inc. has a market cap or net worth of HK$1.19B. The enterprise value is HK$694.38M.
Market CapHK$1.19B
Enterprise ValueHK$694.38M
Share Statistics
CANbridge Pharmaceuticals Inc. has 595,443,360 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding595,443,360
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
CANbridge Pharmaceuticals Inc.’s return on equity (ROE) is -0.04 and return on invested capital (ROIC) is 32.86%.
Return on Equity (ROE)-0.04
Return on Assets (ROA)0.09
Return on Invested Capital (ROIC)32.86%
Return on Capital Employed (ROCE)0.32
Revenue Per Employee746.01K
Profits Per Employee221.16K
Employee Count67
Asset Turnover0.30
Inventory Turnover0.65
Valuation Ratios
The current PE Ratio of CANbridge Pharmaceuticals Inc. is 54.7. CANbridge Pharmaceuticals Inc.’s PEG ratio is -0.75.
PE Ratio54.7
PS Ratio22.72
PB Ratio-3.32
Price to Fair Value-3.32
Price to FCF-29.72
Price to Operating Cash Flow-115.10
PEG Ratio-0.75
Income Statement
In the last 12 months, CANbridge Pharmaceuticals Inc. had revenue of 49.98M and earned 14.82M in profits. Earnings per share was 0.03.
Revenue49.98M
Gross Profit36.55M
Operating Income-92.70M
Pretax Income14.82M
Net Income14.82M
EBITDA-78.98M
Earnings Per Share (EPS)0.03
Cash Flow
In the last 12 months, operating cash flow was -14.10M and capital expenditures -91.00K, giving a free cash flow of -14.19M billion.
Operating Cash Flow-14.10M
Free Cash Flow-14.19M
Free Cash Flow per Share-0.02
Dividends & Yields
CANbridge Pharmaceuticals Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.17
52-Week Price Change1220.00%
50-Day Moving Average2.32
200-Day Moving Average2.36
Relative Strength Index (RSI)44.14
Average Volume (3m)5.03M
Important Dates
CANbridge Pharmaceuticals Inc. upcoming earnings date is Sep 2, 2026, Before Open (Not Confirmed).
Last Earnings DateMar 30, 2026
Next Earnings DateSep 2, 2026
Ex-Dividend Date―
Financial Position
CANbridge Pharmaceuticals Inc. as a current ratio of 0.24, with Debt / Equity ratio of -4.71%
Current Ratio0.24
Quick Ratio0.20
Debt to Market Cap0.01
Net Debt to EBITDA0.64
Interest Coverage Ratio-42.67
Taxes
In the past 12 months, CANbridge Pharmaceuticals Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
CANbridge Pharmaceuticals Inc. EV to EBITDA ratio is -13.74, with an EV/FCF ratio of -28.40.
EV to Sales21.71
EV to EBITDA-13.74
EV to Free Cash Flow-28.40
EV to Operating Cash Flow-28.40
Balance Sheet
CANbridge Pharmaceuticals Inc. has HK$1.96M in cash and marketable securities with HK$34.97M in debt, giving a net cash position of -HK$33.01M billion.
Cash & Marketable SecuritiesHK$1.96M
Total DebtHK$34.97M
Net Cash-HK$33.01M
Net Cash Per Share-HK$0.06
Tangible Book Value Per Share-HK$0.80
Margins
Gross margin is 73.13%, with operating margin of -185.46%, and net profit margin of 29.65%.
Gross Margin73.13%
Operating Margin-185.46%
Pretax Margin29.65%
Net Profit Margin29.65%
EBITDA Margin-158.02%
EBIT Margin-185.46%
Analyst Forecast
The average price target for CANbridge Pharmaceuticals Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-41.19%
EPS Growth Forecast―